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Abstract 
Unlike many other well-characterized 
bacteria, the opportunistic human 
pathogen Pseudomonas aeruginosa 
relies exclusively on the Entner–
Doudoroff pathway (EDP) for glycolysis. 
Pyruvate kinase (PK) is the main 
“pacemaker” of the EDP, and its activity 
is also relevant for P. aeruginosa 
virulence. Two distinct isozymes of 
bacterial PK have been recognized, PykA 
and PykF. Here, using growth and 
expression analyses of relevant PK 
mutants, we show that PykA is the 
dominant isoform in P. aeruginosa. 
Enzyme kinetics assays revealed that 
PykA displays potent K-type allosteric 
activation by glucose 6-phosphate and by 
intermediates from the pentose 
phosphate pathway. Unexpectedly, the X-
ray structure of PykA at 2.4 Å resolution 
revealed that glucose 6-phosphate binds 
in a pocket that is distinct from the 
binding site reported for this metabolite 
in the PK from Mycobacterium 
tuberculosis (the only other available 
bacterial PK structure containing bound 
glucose 6-phosphate). We propose a 
mechanism by which glucose 6-
phosphate binding at the allosteric site 
communicates with the PykA active site. 
Taken together, our findings indicate 
remarkable evolutionary plasticity in the 
mechanism(s) by which PK senses and 
responds to allosteric signals. 
___________________________________ 
Introduction 
Pyruvate kinase (EC.2.7.1.40) is a key 
enzyme in glycolysis, and a major site of 
pathway regulation. The enzyme catalyses 
the conversion of phosphoenolpyruvate and 
ADP into pyruvate and ATP (1). Given its 
central position in metabolism, pyruvate 
kinase (PK) activity can have a major impact 
on the carbon economy of the cell (2, 3). 
More recently, it has been shown that PK 
activity can also influence pathogencity (4). 
Bacterial PK is encoded by two isozymes, 
pykA and pykF (5–7). Most organisms 
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encode either pykA or pykF, although a few 
species also encode both isozymes. Among 
the organisms encoding both pykA and pykF 
that have been characterised to date, PykF 
is usually the dominant isoform. The PykA 
and PykF isozymes have been especially 
well-studied in the Enterobacteriaceae, and 
are distinguished by being differentially 
regulated and cladistically-distinct (at a 
sequence level). For example, PykF 
isozymes are typically activated by fructose 
1,6-bisphosphate (F1,6P) (8), whereas PykA 
is activated by adenosine 5’ monophosphate 
(AMP) (9). Several crystal structures are 
available for PykF isozymes, although no 
structures have been solved for PykA. 
Recently, the structure of Mycobacterium 
tuberculosis PK bound to AMP and glucose 
6-phosphate was solved (the first structure to 
be solved for a bacterial PK with bound 
allosteric regulators). The regulators were 
found to bind at distinct sites in the allosteric 
cleft and were proposed to communicate 
with the active site through a series of 
domain re-orientations denoted the “rock-
shape-lock” mechanism.      
Pseudomonas aeruginosa is an 
opportunistic pathogen which commonly 
causes pulmonary (10), urinary tract (11), 
and soft tissue-associated infections in 
hospitalized patients. The pathogen is 
intrinsically resistant to most clinically-used 
antibiotics (12) and was recently designated 
by the World Health Organisation (WHO) as 
a “critical priority pathogen”. Unlike the 
Enterobacteriaceae, which mainly employ 
the Embden-Meyerhof-Parnas (EMP) 
pathway for glucose catabolism, P. 
aeruginosa lacks phosphofructokinase and 
utilizes the Entner-Doudoroff pathway (EDP) 
instead (13, 14). As a consequence, PK is 
likely to be the major site of glycolytic flux 
regulation in this organism. P. aeruginosa 
encodes two uncharacterized PK isozymes, 
annotated as pykA (PA4329) and pykF 
(PA1498). Here, we show that in contrast 
with most organisms encoding both PK 
isozymes, in P. aeruginosa, PykA plays the 
dominant physiological role. We also present 
the first structure of a PykA isozyme. 
Surprisingly, this structure revealed that 
glucose 6-phosphate binds in a site distinct 
to that observed for the M. tuberculosis 
enzyme.  
Results 
PykA is the dominant pyruvate kinase 
isozyme in P. aeruginosa 
P. aeruginosa encodes two PK isozymes; 
PykA (PA4329, 58% amino acid identity with 
E. coli PykA) and PykF (PA1498, 37% amino 
acid identity with E. coli PykF). An alignment 
of selected relevant PykA and PykF 
sequences is shown in Figure S1. 
Phylogenetic classification of P. aeruginosa 
PykA and PykF (Figure S2) indicates that the 
isozymes belong to two distinct sub-classes 
of PK. To establish which isozyme is 
dominant in P. aeruginosa, we measured the 
PK activity in cell extracts of mutants 
defective in pykA, pykF, or pykA and pykF 
together (pykA pykF). Following growth on 
minimal medium containing glucose, 
glycerol, or acetate as a sole carbon source, 
pyruvate kinase activity was >90% lower in 
the pykA mutant and in the pykA pykF mutant 
than it was in the wild-type control (Figure 1). 
However, pyruvate kinase activity in the pykF 
mutant remained high on these substrates. 
These data indicate that PykA contributes 
most to PK activity in P. aeruginosa. 
Consistent with this, western analyses using 
antibodies raised against purified P. 
aeruginosa PykA or PykF confirmed that the 
latter is essentially undetectable during 
growth on the carbon sources tested unless 
over-expressed in trans from a plasmid 
(Figure 1). Note that the antibodies were pre-
absorbed against a pykA mutant (for the anti-
PykA antibodies) or a pykF mutant (for the 
PykF antibodies). The absence of PykF 
expression in a pykA mutant led to weak 
cross-reactivity of the anti-PykA antibodies 
against shared PykA/PykF epitopes in PykF, 
although this was only apparent when PykF 
was over-expressed. We conclude that pykA 
is expressed at higher levels in these 
conditions than pykF.     
To explore the phenotypic consequences of 
pykA and pykF mutation, we assessed the 
growth characteristics of each mutant on 
different carbon sources (Figure 1). The 
pykA mutant and the pykA pykF mutant grew 
slowly compared with the wild-type and the 
pykF mutant in minimal media containing 
glucose or glycerol as a sole carbon source. 
That there was any observable growth of 
these mutants at all on glucose is 
 Structure and regulation of PykA 
3 
 
presumably due to the pyruvate produced at 
the 2-keto-3-deoxy-6-phosphogluconate 
(KDPG) aldolase-catalyzed step of the EDP. 
Similarly, the slow, but non-negligible growth 
in glycerol (which feeds in to the EDP after 
the KDPG aldolase-catalyzed step) can be 
rationalized by invoking operation of the 
recently-defined EDEMP cycle (15). The 
EDEMP cycle allows triose phosphates such 
as those derived from glycerol to be recycled 
through the KDPG aldolase step, thereby 
yielding pyruvate. Growth on glucose or 
glycerol was restored in the pykA mutant and 
the pykA pykF mutant by expression of either 
pykA or pykF in trans, suggesting that both 
isozymes have the potential to complement 
the pykA mutant growth defect. These data 
also indicate that the low PK activity in the 
pykA mutant is likely due to low expression 
of PykF, rather than low intrinsic activity of 
the isozyme. Consistent with this, pyruvate 
kinase activity increased and PykF 
expression became detectable during 
growth on glucose when pykF was 
expressed in trans in the pykF mutant 
(Figure 1). [PykF is predicted to be part of a 
bicistronic operon alongside a putative 
glycerate kinase, PA1499. The ppykF+ 
complementation plasmid encoded both 
PA1499 and pykF, see Materials and 
Methods.] In contrast, during growth on 
acetate, the pykA, pykF, and pykA pykF 
mutants all grew at essentially the same rate 
as the wild-type. This suggests that PykA 
plays an important role in catabolising 
substrates that feed into the EDP such as 
glucose and glycerol, but contributes less to 
growth on acetate (which does not require 
flux through the PK catalysed reaction). 
Kinetic properties and regulation of PykA 
Purified PykA was an approximately 200 kDa 
tetramer in solution based on analytical 
ultracentrifugation data (Figure S5, S6). At 
saturating phosphoenolpyruvate (PEP) 
concentration, the enzyme displayed 
Michaelis-Menten kinetics with respect to 
[ADP], with a KM value of 0.07mM (Figure 2, 
Table S1). In contrast, at saturating ADP 
concentration, the PEP-dependency was 
sigmoidal, with an S0.5 value of 0.67mM 
(Figure 2, Table S1) and a Hill coefficient of 
2.14, indicative of positive cooperativity.  
All PK enzymes require divalent cations for 
activity (mostly Mg2+), and some have also 
been reported to require K+ in order to 
achieve maximum catalysis (16). The 
presence of these ions is important to 
facilitate binding of the substrate, transfer of 
the phosphoryl group from PEP to ADP, and 
possibly also acquisition of an active enzyme 
conformation (17, 18). We found that the 
activity of P. aeruginosa PykA was 
independent of K+ concentration (Figure 2). 
Indeed, addition of monovalent cations (K+, 
NH4+ or Na+) even somewhat decreased the 
overall catalytic activity of the enzyme 
(Figure S7, Table S1). The K+-mediated 
activation of pyruvate kinase activity is 
known to be dependent on the nature of the 
residue immediately preceding strand Bβ1 in 
the structure (19); in K+-dependent enzymes, 
this residue is a glutamate, whereas in K+-
independent enzymes, it is often a lysine. In 
P. aeruginosa PykA, the corresponding 
residue is a lysine (Figure S1). 
Pyruvate kinase is a major site for the 
regulation of glycolytic flux in many species, 
and most of the known regulators in other 
species are associated with the EMP. 
However, P. aeruginosa relies solely on the 
EDP for glycolysis. To investigate the 
regulation of P. aeruginosa PykA further, we 
screened a wide range of metabolic 
intermediates – guided by a knowledge of 
the pathways feeding in and out of the EDP 
- for their ability to activate or inhibit PykA in 
vitro. Putative regulatory molecules were 
screened at low PEP concentration (0.3 mM) 
to identify activating ligands, and high PEP 
concentration (3 mM) to identify inhibitory 
ligands (Figures 2 and S8, respectively). 
More detailed kinetic analyses (S0.5, kcat) 
were carried out on the “hits” identified this 
way (Figure 2 and S9, Table S1). No 
inhibitors were identified. However, PykA 
was strongly activated by glucose 6-
phosphate (G6P) from the EDP and by 
intermediates from the reductive PPP 
(fructose 6-phosphate (F6P), glyceraldehyde 
3-phosphate (G3P), ribose 5-phosphate 
(R5P), ribulose 5-phosphate (RL5P) and 
xylulose 5-phosphate (X5P)). The main 
effect of these regulators was to decrease 
S0.5, suggestive of K-type allosteric 
regulation, and to change the substrate 
dependency kinetics on PEP from a 
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sigmoidal to a hyperbolic (i.e., Michaelis-
Menten) profile. Although these regulators 
had a large impact on the PEP-dependency 
of the reaction, they had little or no effect on 
its ADP-dependency. Interestingly, AMP and 
fructose 1,6-bisphosphate (two well-
established regulators of PK in many other 
species) had almost no effect on PykA 
activity.      
Structure of PykA 
Currently, there is no structure available for 
any PykA isozyme. We were therefore 
fortunate to obtain crystals of PykA 
containing a substrate analogue (malonate) 
and Mg2+ bound in the active site, and a 
bound allosteric regulator (G6P). The 
crystals diffracted x-rays to 2.4 Å resolution. 
The asymmetric unit of PykA contained 12 
polypeptides assembled into three complete 
homotetramers. This quaternary structure is 
consistent with analytical ultracentrifugation 
analyses (AUC) data indicating that PykA is 
a tetramer in solution (Figure S6). 
Refinement statistics are shown in Table 2.  
Each protomer of PykA had the typical 
tripartite domain organization associated 
with PKs, with the A and C domains of one 
protomer interacting with the A and C 
domains (respectively) from the adjacent 
protomers (Figure 3A,B). The A domain is 
comprised of 8 α/β structures assembled into 
a TIM barrel motif. Helices Aα6 and Aα8 are 
further subdivided into shorter segments 
forming Aα6’ and Aα8’. The Aα6’helix 
contains part of a highly conserved segment 
(M245VARGDLGVE254) which plays a key role 
in catalysis (Figure 3C). The active site is 
located in the cleft between domains A and 
B (Figure 3B). Relative to the A domain, the 
spatial disposition of the β-rich B domain 
varied somewhat between the different 
protomers, indicating that the domain is 
configurationally flexible as a unit. The αβ-
rich C domain contains the bound allosteric 
regulator, G6P.   
The PykA active site contains a bound 
substrate analogue, malonate (present in the 
crystallization buffer) and Mg2+ (Figure 3C). 
The malonate is bound by hydrogen bonds 
from both the polypeptide backbone 
(residues Gly249 (2.8 Å) and Asp250 (3.1 Å)) 
and the sidechains of Lys221 (2.9 Å), Thr282 
(2.6 Å) and Arg34 (3.3 Å). In addition, the 
active site Mg2+ also contributes to malonate 
binding through electrostatic interactions. 
The Mg2+ is octahedrally coordinated 
through interactions with the sidechains of 
Glu223 and Asp250, and also with two water 
molecules. These active site residues are 
absolutely conserved in all bacterial PKs 
(Figure S1), as is their spatial disposition, 
even when comparing malonate-bound 
PykA with pyruvate-bound PK from rabbit 
muscle (PDB 1F3W) (Figure 3D). In contrast, 
superposition of the PykA active site with that 
of E. coli apo-PykF (PDB 1PKY) reveals that 
almost all the residues just discussed 
undergo significant spatial re-orientation in 
the presence of the substrate, indicative of 
induced fit (Figure 3E).  
An alignment of PykA sequences reveals 
that all PykA orthologues contain 3 residues 
not present in any of the PykF orthologues, 
corresponding to Ala229, Asp230 and Asp231 in 
P. aeruginosa PykA (Figure S1). The 
presence of these three additional residues 
lengthens the loop connecting Aα5-Aβ5 
resulting in the displacement of helix Aα5 
away from the core of the enzyme (Figure 
S10). The functional significance of this is not 
yet clear, although it is worth noting that the 
same loop of structure contributes two key 
residues to the active site; Glu223 and Lys221 
(Figure S10). 
Kinetic analysis indicated that G6P is an 
activator of PykA, increasing the apparent 
catalytic efficiency (kcat/S0.5) of the enzyme 
around 3-fold (Table S1 and Figure 2,S9). 
Inspection of the PykA structure revealed a 
molecule of G6P buried in each C-domain, 
far from the active site, indicating that G6P is 
an allosteric regulator (Figure 3B). The 
structure of only one other bacterial PK with 
bound regulator has been solved, and that is 
the PykF family enzyme from M. tuberculosis 
(Mtb). A comparison of the allosteric binding 
site(s) observed in the Mtb enzyme reveals 
AMP bound in the same location as the G6P 
in P. aeruginosa PykA. The Mtb enzyme 
does bind G6P, but the ligand is located in 
an entirely different position in the allosteric 
cleft (PDB 5WSB) (Figure 4A).  
The G6P binding pocket in PykA is 
comprised of two loops; a “phosphate loop” 
and a “ring loop”. The phosphate loop (Cβ1-
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Cα2, residues 383-388) and partly the Cα2 
helix (Thr389) binds the phosphate group of 
the ligand, whereas the ring loop (Cβ4-Cβ5, 
residues 460-471) anchors the hexose ring 
moiety. Superposition of the G6P binding site 
in PykA with the PykF apo-enzyme (1PKY) 
from E. coli reveals that in the presence of 
G6P, the ring loop of PykA is pulled tightly 
over the allosteric pocket (Figure 4B), 
whereas the phosphate loop shares a similar 
disposition in both structures. The movement 
of the ring loop in the presence of G6P 
causes a shift and partial unwinding of the 
Cα4 helix in PykA.  
The bound G6P interacts with the 
surrounding residues through a network of 
hydrogen bonds involving both the 
phosphate group and the sugar ring 
hydroxyls (Figure 4C). In addition, 
occupation of the allosteric site also appears 
to promote secondary interactions between 
the phosphate loop and the ring loop of 
PykA; Ser386 and Thr389 on the phosphate 
loop form hydrogen bonds with Gln467 and 
Thr470 on the ring loop, respectively. 
Interestingly, Lys460 and Tyr464 on the ring 
loop also interact, tightening up closure of 
the binding pocket (Figure 4D). This may be 
unique to the PK sub-class represented by 
P. aeruginosa PykA, because its ring loop is 
less well conserved than the ring loop in 
other PykA enzymes (Figure S1). 
Furthermore, half of the residues that 
mediate the interaction between the 
phosphate and the ring loops are unique to 
P. aeruginosa PykA (Lys460, Tyr464, Gln467).   
Comparison of the G6P-bound PykA 
structure with the E. coli apo-PykF structure 
(1PKY) revealed differences in the 
disposition of residues at the protomer 
interfaces. The PykA tetramer contains four 
inter-protomer interfaces, two of which are 
between adjacent A-domains (A-A interface) 
and two between adjacent C-domains (C-C 
interface) (Figure 3A). The A-A interface 
(approximately 1450 Å2) is formed through 
pairing of Aα6, Aα6’, Aα7, Aα8, loop Aα6-
Aα6’, loop Aα7-Aβ7 and loop Aα8-Cα1 from 
one protomer with the same secondary 
structural units (albeit, with inverted 
symmetry) on the second protomer (Figure 
S11). By contrast, the apo-structure of PykF 
does not include Aα6’ or loop Aα8-Cα1 as 
parts of the interface and instead, there is an 
Aα7-Aα7 interaction which is absent in PykA 
(Figure 5A). The A-A interface in PykA is 
very close to the active site, so structural 
changes at the interface affect the 
disposition of active site residues including 
Arg248, Gly249, Glu283, Asp250 and Thr282 
(Figure S12). Indeed, the mainchain amide 
nitrogen of Gly249 is directly involved in 
binding the substrate analogue, whereas the 
amide carbonyl moiety of this residue forms 
a hydrogen bond with the side chain of Arg296 
on helix Aα7 on the adjacent protomer 
(Figure 5C). The A-A interface is stabilized 
by just two salt bridges (Figure S13), which 
contrasts with the situation seen in E. coli 
apo-PykF, where most of the interactions at 
the A-A involve salt bridges. 
Comparison of G6P-bound PykA with apo-
PykF (1PKY) also reveals major differences 
at the C-C interface (Figure 5B). The C-C 
interface in PykF is comprised of Cα4, Cβ5, 
and the ring loop between Cβ4 and Cβ5. By 
contrast, the C-C interface in PykA is 
comprised of Cβ5, the ring loop, Cα1 and the 
long, flexible loop between Aα8-Cα1. 
Essentially, the bound G6P in PykA 
displaces the ring loop and Cα4, resulting in 
an outward movement of Cα1. This drags the 
Aα8-Cα1 loop region closer towards the C-C 
interface (Figure 5EF). This movement of the 
Aα8-Cα1 loop could, in turn, communicate 
the conformational change from the G6P-
binding site to the A-A interface and the 
active site, providing a plausible mechanism 
by which the allosteric regulator elicits its 
effect. 
Discussion 
Consistent with its role as the major PK 
isozyme in P. aeruginosa, a pykA mutant 
was defective in growth on glucose and 
glycerol. These data raise the question of 
why P. aeruginosa encodes two distinct PK 
isozymes? This is intriguing, especially given 
that the gene encoding one of the isozymes 
(pykF) appeared to show negligible 
expression under any of the growth 
conditions tested. One likely solution is that 
pykF appears to be part of a larger cluster of 
genes (PA1498-PA1502) that may be 
involved in the catabolism of compounds 
such as ethylene glycol (20). Therefore, 
although artificially-expressed pykF is 
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capable of rescuing the growth defect 
associated with the pykA mutant (Figure 1), 
its expression is likely to be induced only 
under very select conditions.    
P. aeruginosa lacks phosphofructokinase 
(encoded by pfk) and is therefore incapable 
of carrying out the EMP pathway of 
glycolysis (13). Instead, and in common with 
around 13% of species for which a genome 
sequence is available, it is exclusively reliant 
on the EDP for glucose oxidation (21). In this 
pathway, pyruvate kinase is the major 
regulatory enzyme. PykA activity was 
activated primarily by G6P, F6P, G3P and by 
intermediates of the reductive PPP. In many 
organisms, the upper arm of the reductive 
PPP is “fed” by the conversion of 6-
phosphogluconate into ribulose 5-
phosphate; a reaction catalysed by 6-
phosphogluconate dehydrogenase (gnd) 
(22–24). However, and like many other 
bacteria that exclusively utilise the EDP, P. 
aeruginosa does not encode a homologue of 
gnd (13, 25). As a consequence, carbon can 
only flow into the PPP from G3P or from 
gluconeogenesis-derived F6P (Figure 6) 
(26). Not surprisingly, given the lack of 
redundancy in input pathways, many of the 
PPP-encoding genes are essential in P. 
aeruginosa (26). It is therefore logical that P. 
aeruginosa has evolved to coordinate 
glucose oxidation with the supply of 
biosynthetic precursors by titrating both 
gluconeogenic and PPP intermediates. 
These two anabolic pathways are tightly 
inter-twined; as shown in Figure 6, EDP-
derived G3P, and F6P derived from 
gluconeogenesis also play a central role in 
the cyclical series of sugar phosphate 
interconversions which comprise the 
reductive PPP. High levels of these, and 
other key PPP intermediates (R5P, X5P and 
RL5P) are presumably physiological 
indicators that biosynthetic precursors are 
abundant (27), and that carbon flux can be 
redirected towards energy production via 
PykA activation. Similarly, high levels of G6P 
indicate sufficiency of either glucose supply 
or of gluconeogenic flux, so it makes good 
metabolic sense that this too should feed 
forward to stimulate PykA, and thence, 
carbon catabolism.  
The only other bacterial PK structure 
containing bound regulatory ligands is the 
PK from M. tuberculosis (28). That work 
revealed that AMP binds in the heart of the C 
domain (Figure 4A), and that G6P binds at 
the interface between the A and C domains. 
However, P. aeruginosa PykA was 
insensitive to AMP, and G6P was found to be 
bound to the same site as that occupied by 
AMP in the Mtb structure. This indicates that 
although the allosteric binding pocket is 
conserved as a cavity in PykA, there is 
considerable evolutionary plasticity in 
regulator binding. That different enzymes 
from the same family (albeit, from different 
species) have evolved to bind the same 
allosteric regulator (G6P) in different sites is 
remarkable, especially from the perspective 
of allosteric transitions. Moreover, and given 
the radically-different structures of ring-sugar 
phosphates such as G6P and F6P compared 
with “configurationally locked” straight-chain 
forms such as RL5P and X5P, this suggests 
that the latter may well bind PykA at other, 
yet-to-be-characterised sites.   
Unfortunately, we were unable to obtain 
crystals of apo-PykA that diffracted beyond 
ca. 4Å. We therefore based our structural 
comparisons on the PykF apo-enzyme from 
E. coli, which does not contain bound 
substrate or regulatory ligands. In the PykF 
structure, the allosteric pocket is open, and 
is uncapped by the ring loop (29). This 
unbound configuration allows the Cα4 
helices to form prominent interactions across 
the C-C interface. However, when the 
allosteric site becomes occupied by G6P, the 
ring loop is pulled down towards the ligand. 
This partially displaces Cα4 and firmly closes 
the allosteric pocket through interactions with 
both the ligand and the phosphate loop. The 
new configuration of the allosteric site seems 
to loosen up the interactions from Cα4, 
concomitantly recruiting other structures to 
the interface, most notably Cα1 and the Aα8-
Cα1 loop (Figure 5). Thus, in PykA, the Aα8-
Cα1 loop contacts two protomers 
simultaneously via the A-A interface and the 
C-C interface. Given the proximity of the A-A 
interface with the active site, this suggests a 
likely mechanism by which G6P binding may 
influence catalysis. Figure 7 illustrates this 
proposed mechanism. G6P-binding to the 
allosteric pocket leads to movement of the 
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ring loop, which displaces Cα4 and allows 
outward movement of Cα1. This, in turn, 
leads to a re-structuring of the Aα8-Cα1 
loop, which directly or indirectly affects the A-
A interface, especially Aα6’ (which forms 
part of the active site). This proposed 
mechanism contrasts with the rigid-body 
“rock-shape-lock” mechanism proposed for 
Mtb PK (28). 
Materials and Methods 
For primers and bacterial strains see Table 
S1. 
Construction of mutants 
The pykA and pykF mutants used were from 
the Washington Mutant Library (identities 
PW8308 (pykA-B04::ISlacZ/hah, which 
carries a Tn insertion at position 903/1452) 
and PW3705 (pykF-C02::ISphoA/hah, which 
carries a Tn insertion at position 213/1434), 
respectively). The insertion site of the 
transposon in each mutant was confirmed by 
PCR using the primers recommended by the 
library curators. To generate the pykA pykF 
double mutant, we first had to remove the 
TetR marker from the pykA mutant. This was 
done by introducing plasmid pFLP2-cre into 
the pykA mutant by electroporation (to 
enable site-specific cre-mediated excision of 
the transposon) followed by plasmid curing 
on LBA plates containing 5% sucrose 
(pFLP2-cre carries sacB as a counter-
selectable marker). Site-specific excision of 
the TetR marker leaves behind a 63 codon 
scar within the target gene, and this was 
confirmed using PCR (Figure S3). The TetS 
pykA mutant was then used as a recipient for 
the TetR marker from a pykF donor, 
introduced by generalized transduction with 
ϕPA3 as a vehicle (30). The pykA pykF 
double mutant was confirmed using (i) PCR 
to demonstrate the presence of the 63 codon 
scar in the pykA ORF (Figure S3), (ii) the 
absence of a PCR-amplifiable pykF fragment 
in the transductants (Figure S4), and (iii) the 
TetR phenotype of the transductants.  
Construction of complementing plasmids 
To complement the pykA mutant, a region 
encompassing the entire pykA ORF and 500 
bp upstream of this were PCR-amplified 
using primers pykA -pLP170-FD and pykA-
pET19m-RV. The amplified DNA fragment 
was digested with EcoRI and BamHI and 
introduced into similarly-digested pUCP20, 
yielding ppykA+. To complement the pykF 
mutant, we used a different strategy. The 
pykF ORF is predicted to form an operon 
with an adjacent glycerate kinase-encoding 
gene, PA1499. Therefore, we PCR amplified 
the entire region spanning from upstream of 
PA1499 to the 3’ end of pykF (using primers 
PA1499-pLP170-FD and pykF-pET19m-RV 
primers). The amplified DNA fragment was 
digested with EcoRI and HindIII and 
introduced into similarly-digested pUCP20, 
yielding ppykF+.  
Bacterial growth 
The indicated strains/mutants were grown in 
LB overnight and washed twice in PBS. 
Cultures were inoculated to an initial OD600 of 
0.05 in 50 mL of minimal media containing 
the indicated carbon sources and/or 
antibiotics. The cultures were grown at 37ºC 
with vigorous aeration. Samples were taken 
every hour for optical density measurement. 
Each growth curve was carried out in 
triplicate. 
Enzyme assays 
Cultures were grown in 50 mL of minimal 
media containing the indicated carbon 
sources and/or antibiotics. The cultures were 
grown at 37ºC with vigorous aeration. After 
the indicated period of growth, the cells were 
harvested by centrifugation (3220 × g, 15 
min, 4ºC) and resuspended in lysis buffer (50 
mM Tris-HCl, 0.1 M NaCl, pH 7.5) containing 
a protease inhibitor cocktail tablet (Roche, 1 
tablet per 50 mL buffer). The cells were lysed 
by sonication on ice and the lysates were 
clarified by centrifugation. Protein was 
determined using the Bradford assay. PK 
activity was measured using a lactate 
dehydrogenase (LDH) coupled assay. The 
reaction mixtures contained 50 mM Tris-HCl 
pH 7.5, 10 mM MgCl2, 10 U rabbit muscle 
LDH, 0.2 mM NADH, 5 mM PEP and 2 mM 
ADP. Reactions were initiated by the addition 
of an equal volume of cell lysate (normalised 
for protein concentration) and allowed to 
proceed at 37ºC. NADH consumption was 
monitored at 340 nm. Each measurement 
was carried out in triplicate.   
Kinetics of purified PykA 
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Pyruvate kinase activity was measured at 
37ºC in 1 mL reactions containing 50 mM 
Tris-HCl, 10 mM MgCl2, 10 U of rabbit 
muscle LDH, 0.2 mM NADH (pH 7.5). For the 
PEP titrations, [ADP] was kept constant at 2 
mM. For the ADP titrations, [PEP] was kept 
constant at 5 mM. Reactions were initiated 
by addition of purified PykA to a final 
concentration of 0.2 µg/mL. Reaction 
progress was monitored at 340nm. 
Regulator screens were carried out using 1 
mM final concentration of the indicated 
regulator candidates and a fixed 
concentration of either 2 mM ADP and 0.3 
mM PEP (when screening for activators), or 
2 mM ADP and 2 mM PEP (when screening 
for inhibitors). The effect of the “hits” 
identified this way on the detailed kinetics 
were re-measured with 1 mM of each 
potential regulator and variable 
concentrations of PEP and ADP, as above. 
The only exception to this was that F6P, R5P 
and X5P were added at 0.2 mM, 0.15 mM 
and 0.5 mM final concentration, respectively, 
in all experiments. Graphpad prism 7 was 
used to analyse the data and to extract the 
kinetic constants. All experiments were 
carried out in triplicate. 
Western blotting 
Anti-PykA and anti-PykF antibodies were 
raised against purified PykA and PykF 
proteins, respectively (Biogenes.De). The 
PykA and PykF antisera were pre-absorbed 
onto an acetone extract of whole lysate 
protein from a pykA mutant or from a pykF 
mutant, respectively. The primary anti-PykA 
and anti-PykF antibodies were used at 
1:2,000 dilution and 1:3,000 dilution, 
respectively. HRP-conjugated goat anti-
rabbit (1:10,000) was used as a secondary 
antibody. The isocitrate dehydrogenase 
isozyme, ICD, was used as a loading control. 
Antibodies raised against ICD has been 
described previously (31).       
Cloning, expression and purification of 
PykA and PykF 
The ORFs encoding PykA (PA4329) and 
PykF (PA1498) were PCR-amplified from P. 
aeruginosa genomic DNA using primers 
pykA-pET19m-FD and pykA-pET19m-RV 
(for pykA amplification) and pykF-pET19m-
FD and pykF-pET19m-RV (for pykF 
amplification). The amplified ORFs were 
cloned into pET-19m, generating pET-19m 
(pykA) and pET-19m (pykF), respectively. 
Expression from pET-19m yields a TEV 
protease-cleavable N-terminally His6-tagged 
protein product. For protein expression, E. 
coli BL21 (DE3) containing pET-19m (pykA) 
or pET-19m (pykF), as appropriate, was 
grown in 1L of LB containing 50 µg/ml 
carbenicillin and 34 µg/ml chloramphenicol 
at 37oC until the OD600 reached 0.5. The 
temperature was then decreased to 20ºC 
and protein expression was induced by 
adding isopropyl-β-D-thiogalactopyranoside 
(IPTG) to a final concentration of 1mM. 
Following overnight growth, the cells were 
harvested by centrifugation (4000 × g, 30 
min, 4ºC) and re-suspended in 50 mL ice-
cold lysis buffer (50 mM Tris-HCl, 200 mM 
NaCl, 10% (v/v) glycerol, 10 mM imidazole 
(pH 8.0)) containing a dissolved EDTA-free 
protease inhibitor cocktail tablet (Roche). 
The resuspended cells were lysed by 
sonication on ice and the sample was then 
clarified by sedimentation (10,000 × g, 30 
min, 4ºC). The clear supernatant was loaded 
onto an Ni-NTA column that had been 
previously pre-equilibrated with lysis buffer. 
The column was washed overnight with lysis 
buffer. The bound protein was eluted in 50 
mM Tris-HCl, 200 mM NaCl, 10% (v/v) 
glycerol, 250 mM imidazole (pH 8.0). The 
eluted protein was mixed with His6-tagged 
TEV protease (1 mg per 20 mg target 
protein) and loaded into a dialysis bag 
(10,000 MWCO). The sample was dialysed 
overnight against 20 mM Tris-HCl, 100 mM 
NaCl, 5% (v/v) glycerol, 1 mM DTT, 0.1 mM 
EDTA (pH 7.5). After dialysis, the protein 
was transferred into a Falcon tube and 
incubated end-over-end for 2 hr at 4ºC with 
a slurry of Ni-NTA that had been previously 
pre-equilibrated in dialysis buffer. Unbound 
protein was concentrated by ultrafiltration 
(Vivaspin column, 30,000 MWCO) then 
aliquoted and flash frozen in liquid nitrogen. 
The protein concentration was determined 
by spectrophotometry using a calculated 
molar extinction coefficient of 24,410 M-1cm-
1 for PykA and 25,440 M-1cm-1 for PykF. 
Analytical ultracentrifugation (AUC) 
Purified PykA was dialyzed against 20 mM 
Tris-HCl, 100 mM NaCl and 0.1 mM EDTA 
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(pH 7.5) for glycerol removal. The 
centrepieces of the Epon double-sector of a 
Beckman Optima XL-I (AN-60 Ti rotor) were 
filled with 400 µL of purified protein or blank 
buffer. The sample was sedimented at 
29,160 × g, 24 h, 20ºC. Absorbance data 
(280 nm) were acquired every 2 min with 
interference scans collected every minute. 
Data analysis and the calculations of buffer 
viscosity, protein partial specific volumes and 
frictional rations were performed using 
SEDFIT and SEDNTERP (32, 33). 
Amino acid sequence analysis 
Amino acid sequences were extracted from 
UniProt in FASTA format, aligned by Clustal 
Omega (34, 35) and displayed by ESPript 
(36). 
Crystallization of PykA 
PykA was crystallized using the sitting drop 
vapour diffusion method. PykA (22 mg/mL in 
20mM Tris-HCl, 100 mM NaCl, 5% (v/v) 
glycerol, 1 mM DTT, 0.1 mM EDTA, 20 mM 
MgCl2, 2 mM G6P, 2 mM PEP (pH 7.5)) was 
mixed 1:1 with the reservoir buffer (200 nL 
each), which contained 20% (w/v) PEG3350, 
0.1 M BIS-TRIS propane, and 0.2 M 
disodium malonate (pH 7.5). Crystals grew 
within one week. The crystals were mounted 
on nylon loops and cryoprotected in mother 
liquor supplemented with 40% (v/v) glycerol 
before being flash frozen in liquid N2. 
X-ray diffraction and structure refinement 
Diffraction data were collected at the 
Diamond Light Source (Didcot, UK) on 
beamline IO4 (MX14043-47). The PykA 
structure was obtained from molecular 
replacement with Phaser (37) using the 
pyruvate kinase of T. brucei (4HYV) as a 
structural template. Coot (38) was used for 
model building, and refinement was 
performed by BUSTER (39). Table 2 shows 
the data collection and refinement statistics.  
Structural coordinates were deposited in the 
PDB with accession code (6QXL). 
PDBePISA (40) was used for analysis of the 
tetramer and ligand interfaces. Figures were 
generated using CCP4mg and PyMOL (41, 
42). 
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Table 1. The effect of metabolic regulators and monovalent ions on PykA activity.  
PEP titration No 
additive 
0.2 mM 
F6P 
0.15 mM 
R5P 
1 mM G3P 1 mM G6P 1 mM KDPG 0.5 mM X5P 1 mM RL5P 100 mM  
KCl 
100 mM 
NH4Cl 
100 mM  
NaCl 
S0.5  (mM) 0.670 ± 
0.058 
0.159  ± 
0.021 
0.195  ± 
0.017 
0.297  ± 0.017 0.290  ±  
0.026 
0.432  ± 
0.036 
0.209 ± 
0.011   
0.269 ± 
0.012 
1.187 ± 
0.086 
1.402 ± 0.084 1.492 ± 0.116 
Hill Coeff (h) 2.14 ± 
0.34 
1.45  ± 
0.31 
1.65  ± 
0.25 
1.89 ± 0.21 1.78  ± 0.32 1.52  ± 0.18 1.87 ± 0.22 1.61 ± 0.12 2.36 ± 0.28 2.31 ± 0.22 2.42 ± 0.32 
Vmax (mM/min) 0.099 ± 
0.004 
0.096 ± 
0.004 
0.092 ± 
0.003  
0.092  ± 0.002 0.100  ± 
0.003 
0.100  ± 
0.004 
0.110 ± 
0.002 
0.110 ± 
0.002 
0.087 ± 
0.002 
0.130 ± 0.003 0.120 ± 0.004 
kcat (s-1) 431.9 418.8 401.4 401.4 436.3 436.3 479.9 479.9 379.6 567.2 523.6 
kcat/S0.5 
 
(s-1mM-1)
 
644.1 2626 2055 1348 1504 1008 2286 1778 319.8 404.6 350.9 
 
ADP titration 
 
No 
additive 
 
0.2 mM 
F6P 
 
0.15 mM 
R5P 
 
1 mM G3P 
 
1 mM G6P 
 
1 mM KDPG 
 
0.5 mM X5P 
 
1 mM RL5P 
 
100 mM 
 KCl 
 
100 mM 
NH4Cl 
 
100 mM 
 NaCl 
KM  (mM) 0.070 ± 
0.015 
N/A N/A N/A N/A N/A N/A N/A 0.147 ± 
0.020 
0.155 ± 0.026 0.146 ± 0.033 
Vmax (mM/min) 0.080 ± 
0.005 
N/A N/A N/A N/A N/A N/A N/A 0.089 ± 
0.004 
0.067 ± 0.003 0.078 ± 0.005 
kcat (s-1) 349.0 N/A N/A N/A N/A N/A N/A N/A 388.3 292.3 340.3 
kcat/KM 
(s-1mM-1) 
4952 N/A N/A N/A N/A N/A N/A N/A 2633 1876 2321 
Kinetic parameters were calculated using GraphPad Prism from best-fit nonlinear regression analysis of the data. The allosteric sigmoid function was used for 
the PEP titration and the Michaelis-Menten function was used for ADP titration. Abbreviations: F6P, fructose 6-phosphate; R5P, ribose 5-phosphate; G3P, 
glyceraldehyde 3-phosphate, G6P, glucose 6-phosphate; KDPG, 2-keto-3-deoxy-6-phosphogluconate; X5P, xylulose 5-phosphate; RL5P, ribulose 5-
phosphate. N/A: not applicable (the regulator had no significant effect on PykA kinetics compared with the control (no additive present)). The values of kcat were 
calculated using [Et] = [PK monomer]. 
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Table 2. Crystallographic data collection and refinement statistics of PykA. Values in 
parentheses are for the highest resolution shell. 
PDB code 6QXL 
Synchrotron/X-ray source Diamond Light Source 
Beamline IO4-1 
Data collection  
 
Wavelength (Å) 0.9159 
Resolution range (Å) 405.44-2.43 (2.49-2.43) 
Space group P31 2 1 
Unit cell  
  a, b, c, (Å) 182.48, 182.48, 405.04 
  a, b, g (°) 90, 90, 120 
Total reflections 4318494 (226510) 
Unique reflections 292996 (21477) 
Multiplicity 14.7 (10.5) 
Completeness (%) 100.0 (100.0) 
Mean I/sigma(I) 11.1 (1.1) 
Resolution (Å) at mean I/sigma(I) > 2 2.65 Å 
Wilson B-factor 55.5 
R-merge 0.143 (2.210) 
R-meas 0.148 (2.324) 
CC1/2 0.999 (0.642) 
  
Refinement 
 
Resolution range (High res) (Å) 158.03 – 2.43 (2.49-2.43) 
Reflections used in refinement 289310 (21209) 
Reflections used for R-free 14331 (1071) 
R-work 0.227 (0.298 ) 
R-free 0.251 (0.315) 
Number of molecules in the ASU: 12 
Number of non-hydrogen atoms  
  macromolecules 43,331 
  Ligands 306 
  Solvent 2268 
Protein residues  
  RMS (bonds) (Å) 0.014 
  RMS (angles) (°) 1.64 
Ramachandran favoured (%) 96.98 
Ramachandran allowed (%) 2.8 
Ramachandran outliers (%) 0.23 
Average B-factor  
  macromolecules 55.65 
  Ligands 62.51 
  Solvent 50.59 
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Figure legends 
Figure 1: PykA is the dominant PK in P. 
aeruginosa. Upper panel. PK activity of 
the WT and indicated mutants grown in M9 
minimal media supplemented with 20 mM 
glucose, 30 mM glycerol or 40 mM acetate. 
Where indicated, the pykA mutant, the 
pykF mutant, or the pykA pykF double 
mutant were complemented with a plasmid 
expressing pykA (denoted ppykA+) or pykF 
(denoted ppykF+). Cell cultures were 
collected for measurement of enzyme 
activity after 10 h of growth. Middle panel. 
Western blots showing expression of PykA 
and PykF (as indicated) in the different 
carbon sources. Isocitrate dehydrogenase 
(ICD) was probed using anti-ICD 
antibodies as a loading control in each blot. 
The doublet observed when anti-PykA 
antibodies were used to probe cell extracts 
of the pykF mutant expressing pykF in 
trans indicates weak cross-reactivity of the 
anti-PykA antibodies with PykF (the lower 
of the bands in the doublet being PykF). No 
such cross-reactivity was apparent with the 
anti-PykF antibodies. Lower panel. 
Growth of the indicated PK mutants (± 
complementation) in different carbon 
sources. Data represent means ± SD for 
three independent biological replicates.    
Figure 2: Kinetic characterization of 
PykA. (A),(B) PykA kinetics with respect to 
PEP and ADP. The PEP titration was 
carried out using a saturating concentration 
of ADP (2 mM) whereas the ADP titration 
was carried out using a saturating 
concentration of PEP (5 mM). (C) Effects of 
monovalent and divalent cations on PykA 
Activity. MgCl2 and KCl were added at 10 
mM and 100 mM concentration, 
respectively. PEP and ADP were at 
saturating initial concentration (5 mM and 2 
mM, respectively). (D) The effect of 
putative metabolic regulators on PykA 
activity at low [PEP] (0.3 mM). [ADP] was 
fixed at 2 mM. The rationale here was to 
identify potential activatory molecules. 
Potential regulators were added at a final 
concentration of 1 mM, except for F6P, 
R5P and X5P which were added at 0.2 mM, 
0.15 mM and 0.5 mM concentration, 
respectively.  Data of figures A, B, C and D 
represent the mean and standard deviation 
of three independent experiments. (E) 
Lineweaver-Burk plots demonstrating that 
the indicated metabolic molecules primarily 
act to decrease S0.5 of PykA compared with 
control (without regulators).  
Figure 3: X-ray crystal structure of 
PykA. (A) The PykA homotetramer. The A-
A and C-C interfaces are shown. Substrate 
and G6P binding sites are indicated in the 
top left protomer. (B) Domain organization 
of a PykA protomer showing malonate 
bound in the active site and G6P bound in 
the allosteric site. (C) Close-up of the PykA 
active site. The network of interactions 
involved in holding the malonate-Mg2+ 
(orange mesh, Fo-Fc map contoured at 3σ) 
and water molecules are shown. (D) 
Superposition of the side chains involved in 
malonate binding in PykA (green) and 
pyruvate binding in rabbit muscle PK 
(1F3W, light blue). (E) Superposition of the 
side chains involved in malonate binding in 
P. aeruginosa PykA (green) with 
sidechains present in the active site of 
E.coli PykF (1PKY, yellow).  
Figure 4: The G6P binding site in PykA. 
(A) Superposition of the allosteric site in 
PykA from P. aeruginosa (light green) and 
PK from M. tuberculosis (5WSB, blue). The 
G6P in PykA is shown in coral whereas the 
AMP and G6P in Mtb PK are shown in pink 
and yellow, respectively. (B) Superposition 
of the allosteric pocket in G6P-bound PykA 
(light green) and unbound PykF from E. coli 
(yellow). The G6P is shown surrounded by 
an electron density map (orange mesh, Fo-
Fc map contoured at 3σ). (C) Schematic of 
the interactions involved in binding G6P to 
PykA. (D) Interaction of the phosphate loop 
(light green) and ring loop (blue) in the 
G6P-binding site of PykA. The G6P is 
shown as magenta sticks.  
Figure 5: The inter-protomer interfaces 
in PykA. Comparison between (A) the A-A 
interface and (B) the C-C interface in PykA 
and E. coli PykF. Interactions present in 
both PykA and PykF are shown as solid 
black lines. Interactions unique to PykA 
only are shown as black dashed lines. 
Interactions unique to PykF only are shown 
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as yellow dashed lines. (C) Close-up view 
of the A-A interface in PykA showing Arg296 
oriented towards the active site. (D) Close-
up view of the A-A interface in E. coli PykF 
showing Arg292 (equivalent to Arg296 in 
PykA) oriented away from the active site. 
(E) The C-C interface in PykA. G6P is 
depicted as large magenta spheres. (F) 
The C-C interface in E. coli PykF.  
Figure 6: PykA is primarily regulated by 
PPP metabolites. Pathways of glucose 
metabolism in P. aeruginosa are indicated 
by black (EDP), blue (PPP) and yellow 
(EMP) arrows, respectively. Identified PykA 
regulators are boxed and shown in green 
with the respective S0.5 indicated below 
each regulator. Fructose 6-phosphate and 
glyceraldehyde 3-phosphate are depicted 
as part of the PPP to emphasize the 
importance they play in this series of sugar 
interconversions. The S0.5 of PykA without 
regulators is shown in a violet box. 
Abbreviations: RpiA, ribose 5-phosphate 
isomerase; Rpe, ribulose phosphate 3-
epimerase; TktA, transketolase; Tal, 
transaldolase; Fda, fructose 1,6-
bisphosphate aldolase; Fbp, fructose 1,6-
bisphosphatase; KDPG, 2-keto-3-deoxy-6-
phosphogluconate. 
Figure 7. Spatial disposition of key 
secondary structural elements in P. 
aeruginosa PykA and E. coli PykF. Note 
how the movement of the ring loop in PykA 
leads to disruption of the Cα4-Cα4 
interaction and concomitant outward 
movement of Cα1. This, in turn, tugs on the 
Aα8-Cα 1 loop, engaging it with the C-C 
interface. The resulting movement of Aα8 
directly or indirectly affects the A-A 
interface by forming new interactions with 
Aα6-Aα6’. Given that Aα6’ forms part of the 
active site, this set of interactions provides 
a plausible mechanism by which G6P 
binding to the allosteric pocket in the 
structure can lead to altered catalysis. 
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